EM-1421
Small molecule
EM-1421 is one of 23 small molecule programs targeting Cervical Intraepithelial Neoplasia. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Cervical Intraepithelial Neoplasia
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Prometrium
FerringApproved
Aldara
BBausch Health Americas, Inc.
Phase 3
Keytruda
Merck & Co.Phase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 2
Viracept
AAgouron Pharmaceuticals
Phase 2
Hepatitis B Adjuvanted Vaccine
GSKPhase 3
Gardasil-9
BBeijing Health Guard Biotechnology, Inc
Phase 3
Tricor
JJagotec
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EM-1421. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- EErimos Pharmaceuticals